Varicella zoster virus the ACIP recommended a second dose of vaccine before school entry to ensure the maintenance of high levels of varicella immunity. In 2006, the United States Food and Drug Administration approved Zostavax for the prevention of shingles. Zostavax is a more concentrated formulation of the Varivax vaccine, designed to elicit an immune response in older adults whose immunity to VZV wanes with advancing age. A systematic review by the Cochrane Library shows that Zostavax reduces the incidence of shingles by almost 50%. Shingrix is a "V. zoster" vaccine developed by GlaxoSmithKline which was approved in the United States by the
Short-term memory study which compiled normative French data for three short-term memory tasks (Verbal, visual and spatial). They found impairments present in participants between the ages of 55 and 85 years of age. Memory distortion in Alzheimer's disease is a very common disorder found in older adults. Performance of patients with mild to moderate Alzheimer's disease was compared with the performance of age matched healthy adults. Researchers concluded the study with findings that showed reduced short-term memory recall for Alzheimer's patients. Episodic memory and semantic abilities deteriorate early in Alzheimer's disease. Since the cognitive system includes interconnected and reciprocally influenced neuronal networks,